Probiotic in Patients With Bile Acid Malabsorption/Diarrhea

Description

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.

Conditions

Bile Acid Malabsorption, Bile Acid Diarrhea

Study Overview

Study Details

Study overview

The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.

Randomized, Double-Blind, Placebo-Controlled Trial of De Simone Formulation Probiotic in Patients With Bile Acid Malabsorption/Diarrhea Unassociated With Ileal Resection

Probiotic in Patients With Bile Acid Malabsorption/Diarrhea

Condition
Bile Acid Malabsorption
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Prior diagnosis of bile acid malabsorption documented in the medical history based on
  • * either serum C4 \>52.5ng/mL, or
  • * fecal 48h total BA excretion \>2337 μmol/48h, or
  • * primary BA \>5% 48h stool collection or \>10% in single stool sample.
  • * 7-day stool dairy with an average stool consistency based on the Bristol Stool Form Scale, BSFS, with a grade greater than 5. Note: If Inclusion criteria 3 is not met, participants may choose to have their blood drawn clinically to further determine eligibility.
  • * For women of childbearing potential
  • * A negative urine pregnancy test prior to dispensing the study product
  • * Agreement to comply with approved methods of contraception during the whole study: unless they meet the criteria of post-menopausal, i.e. 12 months of spontaneous amenorrhea, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner, should use one or more of the following acceptable methods of contraception that should be maintained throughout the study:
  • * Surgical sterilization
  • * Hormonal contraception (implantable, patch, oral, intra-muscular)
  • * Intra-uterine device
  • * Double barrier method (diaphragm plus condom)
  • * At the discretion of the investigator, total abstinence is acceptable in cases where age, career, lifestyle, or sexual orientation of the patient ensures compliance
  • * Use of oral antibiotics and probiotics within the last 4 weeks.
  • * Pregnancy or lactation.
  • * Concomitant use of bile acid sequestrants, must stop 10 days before starting 7-day stool dairy and for the duration of the study.
  • * History of ileal resection.
  • * Diabetes mellitus (type 1)
  • * BMI ≥ 40 kg/m\^2
  • * Diagnosis of gastrointestinal diseases that are associated with inflammation such as inflammatory bowel diseases and celiac diseases or gastrointestinal infection in the prior 4 weeks
  • * Any condition or personal circumstance that, in the opinion of the investigator, renders the subject unlikely or unable to comply with the full study protocol or could interfere with the study assessments

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Michael Camilleri, MD, DSc, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-09-30